Hangover Drink – Nano Hydration
Management Forcast For 2022
Hires Social Media Influencer – 4 Mill Strong
NOHO, Inc. develops, markets, sells and distributes a functional lifestyle beverage category product NOHO-The Hangover Defense. Its flagship product is a dietary supplement, taken before or during the consumption of alcohol that may help to prevent the symptoms associated with a hangover.
The company drink ” After Shot ” provides rapid morning recovery through hydration on a nano scale, providing cells with nutrient rich nano sized water clusters activating your cellular metabolic recovery.
These shares trade in the sub penny category at $0.0006 which is at their 20 day M/A The average daily volume is 67 million shares. The company is a start up, however recently DRNK has hired a very strong marketing and social media team with a superior reputations for branding .
Serious investors should watch carefully for an increase in volume and price that may indicate a surge in product sales . Any break above $0.0009 , its 50 day M/A and 82 mill daily shares may indicate a BREAKOUT
NOHO, INC. PROVIDES OPERATIONS UPDATE AND FORECAST FOR 2022
Scottsdale, Arizona, Dec. 02, 2021 (GLOBE NEWSWIRE) — NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the “Company”), announced the following:
Our Company has seen an amazing resurgence in 2021. In a mere eight months, we have brought the financial reporting current, reduced the debt, engaged a top-tier branding agency, developed a new product and created a fully functioning direct to consumer website with new products on the way. And we haven’t even started yet!
The Company has successfully reduced a majority of its total debt in 2021, extinguishing approximately one million dollars of derivative liabilities. Additional debt reduction has continued in Q4.
The After Shot is available on our revamped site created by Eric Stoll and Lifetime Branding . While available for sale across the country, the formal launch of the site will happen in Q1 2022 behind a broad-based marketing campaign including targeting consumers online and through social media.
The Company is proud to announce a product development agreement with Las Vegas-based gaming influencer, D Lucky . On Instagram as DLuckySlots , he commands an audience of 4.1M followers and growing, focused on strategies to gain advantages in playing casino slot machines. As described on the corporate site :
D LUCKY is regarded as one of the most elite slot machine players in the world after setting numerous records for consistent payouts in Casino Slot Play. Now D LUCKY brings his knowledge and expertise to the public, so anyone who is interested in playing slot machines can do so with the inside tips and strategies from the most successful slot machine player in the world.
In addition to the After Shot , new products have already been formulated and packaging design is completed. The first addition to the line will be a nootropics shot, an all-natural formulation designed to provide focus. The Company is seeking to add at least three new products to the NOHO line throughout 2022.
In June of this year, NOHO acquired the RāD8 brand from Sibannac, Inc. (OTC Pink: SNNC), which was created initially around Delta-8 THC. Following a recent reversal from its initial position, the DEA has said that the popular cannabinoid falls under the purview of the 2018 Farm Bill and should be treated as CBD. There are many opportunities for consumer and white-label manufacturing sales that the Company will be pursuing into next year. Currently, the Company can manufacture Delta-8 gummies and vape cartridges in its Scottsdale-based manufacturing facility now shared with Sibannac.
Delta-8 THC is a hemp-based cannabinoid derived from compliant hemp under the 2018 Farm Bill. Delta 8, while a THC derivative, does not fall under the Controlled Substances Act as Marijuana, as long as it is derived from hemp containing less than .3% Delta-9 THC.
The Company will also be executing an awareness campaign beginning in the new year that will feature digital ads as well as physical billboard placement, in addition to interviews with the management team. For new investors, please see our last shareholder call: Event recording .
More from NOHO – in addition to the After Shot , we have developed a new line of products, all leveraging Hydro-Nano technology, which will be rolling out soon. For additional information and product updates, please follow us at www.nohoshot.com and follow NOHO on Twitter at www.twitter.com/nohodrink.
Scottsdale, Arizona , Sept. 30, 2021 (GLOBE NEWSWIRE) — NOHO, Inc. (OTCPINK:DRNK), a Wyoming corporation (the “Company”), announced the following:
The Company intends to raise up to $20 million through a Regulation A Tier II Offering (“Offering”). The proceeds from the offering will be used for brand development and advertising spend as well as general operations. A portion of funding, if available, will also be reserved for acquisition.
After a previous successful transaction with Continuation Capital for the sale of debt with Sibannac, Inc., the firm is expected to issue NOHO a written Indication of Interest in the Offering up to $8 million. The balance of the raise will be allocated between existing shareholders and other institutional and private investors. The Company will be working with its auditor to complete the necessary audits for the Offering. Offering details, including proposed share pricing, will be disclosed upon filing the registration documents.
Product and Operations Update
While Direct to Consumer remains the primary sales model, as part of the product roll-out plan the Company will be focusing resources in Las Vegas and New York for brand awareness and partnership opportunities. The Company has provided a product development agreement to a Las Vegas-based gaming influencer with a substantial social media following, for a beverage additive. NOHO will handling all formulation and product design responsibility. Consummation of the agreement is expected within a week.
The sample product featured on Twitter is a new formulation in the nootropics category. Nootropics are compounds that enhance cognitive performance. This formulation contains only natural, dietary supplements and would not be subject to FDA approval. The Company will be providing more information on this product in the near future.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Noho, Inc. (the “Company”), its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer was paid $250. and owns no shares in this issue .The term Buy List – Buy Watch List referring to a Watch List and not a recommendation to buy. Each individual has their own risk level and should know their risk level and act accordingly . In most cases company management or company agent, checks the article for accuracy and gives approval before publishing